hydroxyurea treatment in transfusion-dependent β-thalassemia patients

Authors

mohammad reza bordbar hematology research center, shiraz university of medical sciences, shiraz, ir iran

samir silavizadeh hematology research center, shiraz university of medical sciences, shiraz, ir iran

sezaneh haghpanah hematology research center, shiraz university of medical sciences, shiraz, ir iran

roza kamfiroozi hematology research center, shiraz university of medical sciences, shiraz, ir iran

abstract

conclusions: hydroxyurea can be safely used in some transfusion-dependent β-thalassemia patients to decrease their transfusion needs. background: β-thalassemia is an inherited hemoglobin disorder caused by defective synthesis of ß-globin chains. hemoglobin (hb) f induction is a possible therapeutic approach which can partially compensate for α and non-α globin chains imbalance. objectives: we aimed to investigate the efficacy and safety of hydroxyurea (hu) in diminishing transfusion requirements of patients with β-thalassemia major in southern iran. patients and methods: in this single-arm clinical trial, all transfusion-dependent β-thalassemia patients older than two years old (n = 97) who had inclusion criteria of the study and had been registered for at least six months in dastgheib thalassemia outpatient clinic (a referral center affiliated to shiraz university of medical sciences) were evaluated from october 2010 to december 2011. the patients were treated with hu with a mean dose of 10.5 mg/kg for a mean duration of 8 months (range 3-14 months). transfusion needs and hb levels were compared before and after hu treatment. results: the mean volume of blood transfusion decreased significantly following hu treatment (0.71 ml/kg/day vs. 0.43 ml/kg/day, p < 0.001). two-thirds of the patients showed good and partial response. no serious adverse reaction was observed except persistent neutropenia in two patients.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Hydroxyurea Treatment in Transfusion-Dependent β-Thalassemia Patients

BACKGROUND β-Thalassemia is an inherited hemoglobin disorder caused by defective synthesis of ß-globin chains. Hemoglobin (Hb) F induction is a possible therapeutic approach which can partially compensate for α and non-α globin chains imbalance. OBJECTIVES We aimed to investigate the efficacy and safety of Hydroxyurea (HU) in diminishing transfusion requirements of patients with β-thalassemia...

full text

Hypothyroidism in β-Thalassemia Intermedia Patients with and without Hydroxyurea

Hydroxyurea (HU) has been successfully used in patients with β-thalassemia intermedia (β-TI). We aimed to evaluate the effect of the long-term use of HU on thyroid function in patients with β-TI. Seventy-five patients with β-TI aged≥11 years and taking HU were randomly selected during 2010 in southern Iran. Thirty-one patients with β-TI without HU were considered as a control group. Serum level...

full text

Prevalence of Diabetes Mellitus in Patients with Transfusion Dependent β Thalassemia

Introduction: Thalassemia is common in Iran. Appropriate therapy for this disease includes a regular blood transfusion and chelation therapy. However, patients will inevitably confront with side effects, particularly iron overloads in critical organ including heart, ductless glands and liver. This study tries to determine the prevalence of diabetes mellitus in transfusion dependent β thalassemi...

full text

Bone density in transfusion dependent thalassemia patients in Urmia, Iran

Background Patients with thalassemia major and intermedia are susceptible to osteopenia and osteoporosis. The mechanism of osteoporosis in these patients is multifactorial. Transfusion related iron overload in endocrine organs leads to impaired growth hormone secretion, diabetes mellitus, hypothyroidism, hypoparathyroidism, lack of sex steroids and vitamin D deficiency that contribute t...

full text

Prevalence of Alloantibodies and Autoantibodies in Transfusion Dependent Thalassemia Patients

Background: The development of anti-red blood cell alloantibodies remains a major problem in transfusion of blood in thalassemia major patients. Also, Autoantibodies can result in clinical hemolysis and difficulty in cross-matching blood. We studied the frequency of red blood cell alloimmunization and autoimmunization among thalassemia patients who received regular transfusions in Ilam province...

full text

Renal Hemosiderosis among Iranian Transfusion Dependent β-Thalassemia Major Patients

Background: In recent years, the success in management of thalassemic patients, has allowed for some previously unrecognized complications including renal abnormalities to emerge. This prospective study aimed to investigate kidney iron overload by means of MRI T2* and also renal function based on laboratory tests for early markers of glomerular and tubular dysfunction among adult Iranian transf...

full text

My Resources

Save resource for easier access later


Journal title:
iranian red crescent medical journal

جلد ۱۶، شماره ۶، صفحات ۰-۰

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023